Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.34 |
| ▸ | TNK2 | Q07912 | 15/20 | 0.33 |
| ▸ | LCK | P06239 | 8/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
| ▸ | MERTK | Q12866 | 1/20 | 0.32 |
| ▸ | AURKA | O14965 | 2/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4750648 | 0.86 | LCK (0.41) | EGFRTNK2LCKJAK2SRC | |
| SCHEMBL1785065 | 0.86 | LCK (0.41) | EGFRTNK2LCKJAK2SRC | |
| SCHEMBL1787517 | 0.84 | EGFR (0.35) | EGFRTNK2LCKJAK2SRC | |
| SCHEMBL3124995 | 0.84 | MERTK (0.34) | TNK2LCKKDRMERTKAURKA | |
| Formic Acid SCHEMBL1787516 | 0.83 | CHRNB4 (0.36) | EGFRTNK2LCKJAK2SRC | |
| SCHEMBL1787145 | 0.83 | CHRNB4 (0.38) | EGFRTNK2LCKJAK2SRC | |
| SCHEMBL14467158 | 0.83 | CHRNB4 (0.38) | EGFRTNK2LCKJAK2SRC | |
| SCHEMBL4788723 | 0.82 | MERTK (0.34) | EGFRTNK2LCKMERTKAURKA | |
| Formic Acid SCHEMBL1787399 | 0.82 | ALOX5AP (0.38) | EGFRTNK2MERTK | |
| SCHEMBL3125001 | 0.82 | AURKA (0.36) | EGFRTNK2LCKMERTKAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324222-B2 | Cyclically substituted furopyrimidine derivatives and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-12-04 | — | — | US | disclosed |
| US-20110124665-A1 | Novel, Cyclically Substituted Furopyrimidine Derivatives and Use Thereof | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124665-A1 | Novel, Cyclically Substituted Furopyrimidine Derivatives and Use Thereof | DPYD, TK2, TPMT | EGFR 4141/4885TNK2 1169/4885LCK 840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.